<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20151003024317N11</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-11</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Target Control Infusion (TCI)  on the Creatine Level of Patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of target control injection (TCI) of anesthetic with conventional method on creatinine level of patients with renal impairment in open heart surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-07-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>66</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48271</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomly assigned to tree groups. In order to randomize, a random block method will be used. For this purpose, we formed blocks of size 6. In each block, 2 individuals will be in intervention group 1, 2 individuals will be in intervention group 2 and 2 will be in control group. A total of 11 blocks will be considered for the study, Blinding description: Surgeons and patients will be kept blind and unaware of the type of anesthesia. Patients will be aware that they will be randomly assigned to one of three treatment groups, but will be unaware of which treatment will be provided in that group. Patients will be assigned to one of three groups using random number tables. The surgeon also knows that patients will be anesthetized in three different ways, but will not know which procedure will be performed for each patient. The data collection officer, analyst, outcome assessor and data safety and Data Safety and Monitoring Committee will collect and analyze information based on groups 1, 2 and 3 and will not be aware of the type of treatment provided in the groups. They will be kept blind.</study_design>
      <phase>3</phase>
      <hc_freetext>Renal impairment in open heart surgery.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: For anesthesia of patients by targeted controlled injection, Remy Fentanyl with a dose of 0.5-1 μ/kg (manufacturer: NORMON,SA(spain)), proponol with a dose of 2 - 2.5 mg/kg (manufacturer: BRUN/B) and Cis Atracurium (Manufacturer: Behin Tamin Rosa Mod Co.) at a dose of 0.15-0.2 mg/kg will be injected. Then, depending on the depth of anesthesia, the drug will injected and whenever the number of BIS reaches between 40 and 60, the patient will intubated and in order to maintenance anesthesia, proponol with a dose of 2-3 μ/ml in patients over 50 years or 3-4 μ/ml in Patients under 50 years, Remy Fentanyl with a dose of 3-6 ng/ml in patients over 50 years and 5-8 ng/ml in patients less than 50 years and finally Cis Atracurium with a dose of 3 μ/ kg/min will be prescribed with TCI technique. Intervention 2: Second intervention group: for anesthesia of patients from Midazolam with a dose of 0.2 - 0.4 mg/kg (manufactured by Exir Company), Fentanyl with a dose of 2-20 μg/kg (manufactured by Caspian Tamin Rasht Factory) and Atracurium with a dose of 0.005 - 0.01 mg/kg/min (manufactured by Abu Reihan Company) Will be infused continuously. Intervention 3: Control group:  For patients undergoing conventional anesthesia, Remy Fentanyl with a dose of 0.5-1 μ/kg (manufacturer: NORMON,SA(spain)), proponol with a dose of 2 - 2.5 mg/kg (manufacturer: BRUN/B) and Cis Atracurium (Manufacturer: Behin Tamin Rosa Mod Co.) at a dose of 0.15-0.2 mg/kg will be injected. Then, depending on the depth of anesthesia, the drug will injected and whenever the number of BIS reaches between 40 and 60, the patient will intubated and in order to maintenance anesthesia, proponol with a dose of 2-3 μ/ml in patients over 50 years or 3-4 μ/ml in Patients under 50 years, Remy Fentanyl with a dose of 3-6 ng/ml in patients over 50 years and 5-8 ng/ml in patients less than 50 years and finally Cis Atracurium with a dose of 3 μ/ kg/min will be injected with a regular pump.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohsen Ziyaei Fard</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rajaie Cardiovascular Medical and Research Center, Next to Mellat Park, Vali-e-Asr St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1995614331</zip>
        <telephone>+98 21 23921</telephone>
        <email>mziyaeifard@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohsen Ziyaei Fard</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rajaie Cardiovascular Medical and Research Center, Next to Mellat Park, Vali-e-Asr St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1995614331</zip>
        <telephone>+98 21 23921</telephone>
        <email>mziyaeifard@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who are candidates for open heart surgery who have creatinine greater than 1.5 mg / dl
Patients over 18 years old</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients over 70 years
Pregnancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I97.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other functional disturbances following cardiac surgery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: For anesthesia of patients by targeted controlled injection, Remy Fentanyl with a dose of 0.5-1 μ/kg (manufacturer: NORMON,SA(spain)), proponol with a dose of 2 - 2.5 mg/kg (manufacturer: BRUN/B) and Cis Atracurium (Manufacturer: Behin Tamin Rosa Mod Co.) at a dose of 0.15-0.2 mg/kg will be injected. Then, depending on the depth of anesthesia, the drug will injected and whenever the number of BIS reaches between 40 and 60, the patient will intubated and in order to maintenance anesthesia, proponol with a dose of 2-3 μ/ml in patients over 50 years or 3-4 μ/ml in Patients under 50 years, Remy Fentanyl with a dose of 3-6 ng/ml in patients over 50 years and 5-8 ng/ml in patients less than 50 years and finally Cis Atracurium with a dose of 3 μ/ kg/min will be prescribed with TCI technique.</i_keyword>
      <i_keyword>Second intervention group: for anesthesia of patients from Midazolam with a dose of 0.2 - 0.4 mg/kg (manufactured by Exir Company), Fentanyl with a dose of 2-20 μg/kg (manufactured by Caspian Tamin Rasht Factory) and Atracurium with a dose of 0.005 - 0.01 mg/kg/min (manufactured by Abu Reihan Company) Will be infused continuously.</i_keyword>
      <i_keyword>Control group:  For patients undergoing conventional anesthesia, Remy Fentanyl with a dose of 0.5-1 μ/kg (manufacturer: NORMON,SA(spain)), proponol with a dose of 2 - 2.5 mg/kg (manufacturer: BRUN/B) and Cis Atracurium (Manufacturer: Behin Tamin Rosa Mod Co.) at a dose of 0.15-0.2 mg/kg will be injected. Then, depending on the depth of anesthesia, the drug will injected and whenever the number of BIS reaches between 40 and 60, the patient will intubated and in order to maintenance anesthesia, proponol with a dose of 2-3 μ/ml in patients over 50 years or 3-4 μ/ml in Patients under 50 years, Remy Fentanyl with a dose of 3-6 ng/ml in patients over 50 years and 5-8 ng/ml in patients less than 50 years and finally Cis Atracurium with a dose of 3 μ/ kg/min will be injected with a regular pump.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Total dose of anesthesia. Timepoint: After surgery. Method of measurement: Based on patient records.</prim_outcome>
      <prim_outcome>Creatinine levels. Timepoint: During surgery, After surgery, 24 hours after surgery. Method of measurement: Based on patient records.</prim_outcome>
      <prim_outcome>Duration of hospitalization in the ICU. Timepoint: During patient discharge. Method of measurement: Based on patient records.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-16</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemmat Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
